Status
Active

Remdesivir compassionate use program

Purpose / Objectives

Primary Outcome

Compassionate use program

Diagnosis

  • COVID-19 (SARS-CoV-2 Infection)
  • Infectiology

Patients with proven SARS-CoV-2 infection

Target population

Inclusion criteria

Informed consent for compassionate use and healing attempt, if possible

Documents (password protected)

Go to download area (no documents yet)

Responsibilities in overall study

Sponsor

Gilead Sciences, Inc.

(National) Coordinating Investigator

Prof. Dr. med. Philipp Köhler